X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CK0803 is a neurotrophic, allogeneic, umbilical cord blood-derived T regulatory (Treg) cell therapy that preferentially homes towards inflamed microglia, developed by using Cellenkos' proprietary CRANE® technology. It is being developed for amyotrophic lateral sclerosis.
Lead Product(s): CK0803
Therapeutic Area: Neurology Product Name: CK0803
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
CK0803 is a novel allogenic cell therapy product consisting of T regulatory cells, with a high cell surface expression of CD11a, that leverage CXCR3/CXCL10 axis. It is being developed for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): CK0803
Therapeutic Area: Neurology Product Name: CK0803
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
CK0804 is a novel allogenic cell therapy product consisting of T-regulatory cells that exploit the CXCR4/CXCL12 axis and are derived from clinical-grade umbilical cord blood units and manufactured using Cellenkos' proprietary process.
Lead Product(s): CK0804
Therapeutic Area: Oncology Product Name: CK0804
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
Through the acquisition, GCBC will acquire the rights to develop and commercialize all of its existing and future products worldwide including CK0802, an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells).
Lead Product(s): CK0802
Therapeutic Area: Infections and Infectious Diseases Product Name: CK0802
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Global Cord Blood Corporation
Deal Size: $664.0 million Upfront Cash: $664.0 million
Deal Type: Acquisition April 29, 2022
Details:
Proceeds from this financing will be used to further its development on the Treg cell therapy platform including CK0802 to address high unmet needs in autoimmune and inflammatory disorders.
Lead Product(s): CK0802
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CK0802
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BVCF Management Ltd
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 04, 2021
Details:
As per the terms of the agreement, the companies plan to initiate a Phase 1b single arm, open-label study evaluating ruxolitinib in combination with CK0804 in patients with myelofibrosis (MF).
Lead Product(s): Ruxolitinib Phosphate,CK0804
Therapeutic Area: Oncology Product Name: Jakafi
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: $294.5 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 30, 2020
Details:
US Food & Drug Administration (FDA) has cleared the way to initiate a Phase 1 clinical trial of CK0802 (Cryopreserved Cord Blood Derived T-Regulatory Cells) for treatment of COVID-19 associated acute respiratory distress syndrome (ARDS).
Lead Product(s): Cord Blood-Derived T-Regulatory Cells
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Cellenkos will utilize its clinical success with CK0802 for other inflammatory diseases, track development of CK0802 to treat COVID-19-induced respiratory complications.
Lead Product(s): CK0801
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
